What is Vertex Pharmaceuticals's share-based compensation expense, net of tax?

Vertex Pharmaceuticals (VRTX) reported share-based compensation expense, net of tax of $147.40M in Q3 2025.

How has Vertex Pharmaceuticals's share-based compensation expense, net of tax changed year-over-year?

Vertex Pharmaceuticals's share-based compensation expense, net of tax increased by 22.8% year-over-year, from $120.00M to $147.40M.

What does share-based compensation expense, net of tax mean?

The after-tax cost of equity-based compensation provided to employees.

Discontinued — last reported Q4 '25

Operating Expenses

Share-Based Compensation Expense, Net of Tax

Vertex Pharmaceuticals Share-Based Compensation Expense, Net of Tax increased by 12.7% to $147.40M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 22.8%, from $120.00M to $147.40M. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementIncome Statement

SectionOperating Expenses

CategoryProfitability

SignalLower is better

VolatilityStable

First reportedQ1 2018

Last reportedQ4 2025

How to read this metric

An increase indicates higher equity-based compensation costs, which may dilute shareholders or reflect increased incentive spending.

Detailed definition

Represents the total expense recognized for share-based payment arrangements, such as stock options or restricted stock...

Peer comparison

Standard across public companies, though accounting methods for tax benefits can vary.

Metric ID: is_ibm_share_based_compensation_net_of_tax

Historical Data

8 periods

	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q2 '24	Q3 '24	Q2 '25	Q3 '25
Value	$103.43M	$103.43M	$103.43M	$103.43M	$73.50M	$120.00M	$130.80M	$147.40M
QoQ Change	—	+0.0%	+0.0%	+0.0%	-28.9%	+63.3%	+9.0%	+12.7%
YoY Change	—	—	—	—	-28.9%	+16.0%	+78.0%	+22.8%

Range$73.50M – $147.40M

CAGR+22.4%

Avg YoY Growth+22.0%

Median YoY Growth+19.4%

Current Streak3 quarters growth

Frequently Asked Questions

What is Vertex Pharmaceuticals's share-based compensation expense, net of tax?: Vertex Pharmaceuticals (VRTX) reported share-based compensation expense, net of tax of $147.40M in Q3 2025.
How has Vertex Pharmaceuticals's share-based compensation expense, net of tax changed year-over-year?: Vertex Pharmaceuticals's share-based compensation expense, net of tax increased by 22.8% year-over-year, from $120.00M to $147.40M.
What does share-based compensation expense, net of tax mean?: The after-tax cost of equity-based compensation provided to employees.